Table 3.
Adverse Effects and Cycle Length After Treatment
| CDB-2914 Users (n = 775) |
Levonorgestrel Users (n = 774) |
P | |
|---|---|---|---|
| Cycle length (d)* | |||
| Before treatment | 29.13 | 29.04 | .36 |
| After treatment | 31.77 | 26.94 | <.001 |
| Change | +2.64 | −2.10 | <.001 |
| Symptoms experienced after treatment (%) | |||
| None | 30 | 30 | .96 |
| Nausea | 29 | 24 | .03 |
| Vomiting | 2 | 2 | .60 |
| Headache | 29 | 29 | .77 |
| Dizziness | 20 | 18 | .36 |
| Fatigue | 37 | 37 | .98 |
| Breast tenderness | 16 | 15 | .81 |
| Lower abdominal pain | 31 | 27 | .08 |
| Diarrhea | 12 | 11 | .84 |
| Spotting† | 4 | 6 | .08 |
| Bleeding† | 1 | 1 | 1.00 |
*
Analysis based on one-way analysis of variance, with treatment as the factor; remainder based on χ2 test.
†
Occurred in more than 25% of follow-up days.